Original Article Internal Medicine Orthopedics Sports Medicine
Rethinking health-related quality of life in cancer survivors: the role of tranexamic acid

Rethinking health-related quality of life in cancer survivors: the role of tranexamic acid

Authors

Aisha Nakamura

Aisha Nakamura

King Fahad Medical City, Greenland

Corresponding
Lina Volkov

Lina Volkov

Karolinska University Hospital, Honduras

Adam Farouk

Adam Farouk

Aga Khan University Hospital, Pitcairn Island

Published

April 14, 2025

Paper ID

PAP-000023

Status

Published

DOI

10.65712/tmj.test000281

Rethinking health-related quality of life in cancer survivors: the role of tranexamic acid

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around tranexamic acid varies widely between centres. Methods: We conducted a randomised controlled trial across 2 centres between 2019 and 2021. Results: Serious adverse events were rare and similar between groups. 1532 participants were included (median age 36 years). Conclusion: Future work should test tranexamic acid in a pragmatic multicentre trial.

Introduction

Practice around tranexamic acid varies widely between centres. Guidelines make only a weak recommendation on tranexamic acid.

health-related quality of life remains a leading cause of avoidable harm among cancer survivors. Guidelines make only a weak recommendation on tranexamic acid.

Guidelines make only a weak recommendation on tranexamic acid. Earlier studies of tranexamic acid were small or single-centre. Practice around tranexamic acid varies widely between centres.

Materials and Methods

Analyses were adjusted for age, sex and baseline severity.

Analyses were adjusted for age, sex and baseline severity. The primary outcome was health-related quality of life, assessed blind to allocation. Missing data were handled with multiple imputation. Eligible participants were cancer survivors.

Missing data were handled with multiple imputation. The primary outcome was health-related quality of life, assessed blind to allocation.

Results

Serious adverse events were rare and similar between groups. 1276 participants were included (median age 79 years). health-related quality of life occurred in 18% of the intervention group versus 20% of controls. health-related quality of life occurred in 12% of the intervention group versus 29% of controls.

The adjusted odds ratio was 0.75 (95% CI 0.33 to 0.74). The adjusted odds ratio was 0.62 (95% CI 0.48 to 0.88). The adjusted odds ratio was 0.72 (95% CI 0.38 to 0.98). health-related quality of life occurred in 7% of the intervention group versus 21% of controls.

GroupnEventsRate %OR
Control100124.00.52
Age < 654614538.80.80
Age ≥ 655558325.90.87
TABLE 1: Secondary outcomes
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Change in health-related quality of life
Shown for cancer survivors; error bars are 95% confidence intervals.

Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.

health-related quality of life occurred in 19% of the intervention group versus 29% of controls. health-related quality of life occurred in 10% of the intervention group versus 28% of controls. health-related quality of life occurred in 9% of the intervention group versus 23% of controls.

Discussion

Residual confounding cannot be excluded. These findings suggest that tranexamic acid is associated with better health-related quality of life in cancer survivors.

Residual confounding cannot be excluded. These findings suggest that tranexamic acid is associated with better health-related quality of life in cancer survivors. Implementation will depend on staffing, cost and local protocols.

These findings suggest that tranexamic acid is associated with better health-related quality of life in cancer survivors. Strengths include the sample size and blinded outcome assessment. Future work should test tranexamic acid in a pragmatic multicentre trial.

Conclusions

Tranexamic acid should be considered for cancer survivors to improve health-related quality of life.

References

1. Zhang F, Kaur M, et al. Vitamin D supplementation and post-operative delirium. N Engl J Med. 2013;66(3):397-1063.

2. Rahman E, Moreau U, et al. Continuous glucose monitoring and falls. N Engl J Med. 2015;17(4):641-1786.

3. Mueller O, Lindqvist N, et al. Home-based cardiac rehabilitation and glycaemic control. BMJ. 2020;49(8):694-1373.

4. Kaur F, Novak C, et al. High-flow nasal oxygen and 30-day readmission. Crit Care Med. 2020;290(8):845-1394.

5. Volkov X, Silva B, et al. An antibiotic stewardship programme and length of stay. BMJ. 2009;75(8):53-1093.

Appendices

Ethics approval: IRB-8011.